Evidence map›Paper›PMID 31813281›Full record

Trial reportCirculation. Heart failure2019

Baseline Characteristics of the VANISH Cohort.

Anna Axelsson Raja, Ling Shi, Sharlene M Day, Mark Russell, Kenneth Zahka, Harry Lever, Steven D Colan, Renee Margossian, E Kevin Hall, Jason Becker and 25 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01912534 (Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01912534 phase2completednot on this map

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

TypeinterventionalSponsorCarelon ResearchRan2014 to 2019Enrolled211ConditionsHypertrophic CardiomyopathyArmsValsartan, Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 4 institutions in 2 countries.

Anna Axelsson RajaCopenhagen University Hospital Rigshospitalet, Denmark (A.A.R., H.B.).
Ling ShiNew England Research Institutes, Watertown, MA (L.S.).
Sharlene M DayUniversity of Michigan, Ann Arbor (S.M.D., M.R.).
Mark RussellUniversity of Michigan, Ann Arbor (S.M.D., M.R.).
Kenneth ZahkaCleveland Clinic, OH (K.Z., H.L.).
Harry LeverCleveland Clinic, OH (K.Z., H.L.).
Steven D ColanBoston Children's Hospital, MA (S.D.C., R.M.).
Renee MargossianBoston Children's Hospital, MA (S.D.C., R.M.).
E Kevin HallYale University, New Haven, CT (E.K.H.).
Jason BeckerVanderbilt University Medical Center, Nashville, TN (J.B.).
John Lynn JefferiesCincinnati Children's Hospital Medical Center, OH (J.L.J.).
Amit R PatelUniversity of Chicago, IL (A.R.P.).
Lubna ChoudhuryNorthwestern University, Chicago, IL (L.C.).
Anne M MurphyJohns Hopkins University School of Medicine, Baltimore, MD (A.M.M.).
Charles CanterWashington University School of Medicine, St. Louis, MO (C.C., R.B.).
Richard BachWashington University School of Medicine, St. Louis, MO (C.C., R.B.).
Matthew TaylorUniversity of Colorado Anschutz Medical Campus, Aurora (M.T., L.M.).
Luisa MestroniUniversity of Colorado Anschutz Medical Campus, Aurora (M.T., L.M.).
Matthew T WheelerStanford University School of Medicine, Palo Alto, CA (M.T.W.).
Lee BensonToronto Hospital for Sick Children, ON, Canada (L.B.).
Anjali T OwensUniversity of Pennsylvania Perelman School of Medicine, Philadelphia (A.T.O.).
Joseph RossanoChildren's Hospital of Philadelphia, PA (J.R., K.Y.L.).
Kimberly Y LinChildren's Hospital of Philadelphia, PA (J.R., K.Y.L.).
Elfriede PahlAnn & Robert H. Lurie Children's Hospital of Chicago, IL (E.P.).
Alexandre C PereiraHeart Institute, University of São Paulo Medical School (Instituto do Coração), Brazil (A.C.P.).
Henning BundgaardCopenhagen University Hospital Rigshospitalet, Denmark (A.A.R., H.B.).
Gregory D LewisMassachusetts General Hospital, Boston (G.D.L.).
Jose D VargasMedStar Georgetown University Hospital, National Institutes of Health, Bethesda, MD (J.D.V.).
Allison L CirinoBrigham and Women's Hospital, Boston, MA (A.L.C., C.A.M., S.D.S., E.J.O., E.B., C.Y.H.).
John J V McMurrayUniversity of Glasgow, Glasgow, UK (J.J.V.M.).
Calum A MacRaeBrigham and Women's Hospital, Boston, MA (A.L.C., C.A.M., S.D.S., E.J.O., E.B., C.Y.H.).
Scott D SolomonBrigham and Women's Hospital, Boston, MA (A.L.C., C.A.M., S.D.S., E.J.O., E.B., C.Y.H.).
E John OravBrigham and Women's Hospital, Boston, MA (A.L.C., C.A.M., S.D.S., E.J.O., E.B., C.Y.H.).
Eugene BraunwaldBrigham and Women's Hospital, Boston, MA (A.L.C., C.A.M., S.D.S., E.J.O., E.B., C.Y.H.).
Carolyn Y HoBrigham and Women's Hospital, Boston, MA (A.L.C., C.A.M., S.D.S., E.J.O., E.B., C.Y.H.).
Cleveland Clinic · USLynn University · USNew England Research Institutes · USUniversity of Glasgow · GB

Funding

Using Genetics For Early Phenotyping & Prevention of Hypertrophic CardiomyopathyP50HL112349 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, CAROLYN Y, SEIDMAN, CHRISTINE E · 2012 to 2017
$11.2M
Using Genetics for Early Phenotyping & Prevention of Hypertrophic CardiomyopathyP20HL101408 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, CAROLYN Y, SEIDMAN, CHRISTINE E · 2010 to 2011
$1.5M
NHLBI NIH HHS P20 HL101408NHLBI NIH HHS P50 HL112349
6 · The paper itself

Abstract

backgroundThe VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease progression. We describe the baseline characteristics of the VANISH cohort and compare to previous trials evaluating angiotensin receptor blockers.

methodsApplying a randomized, double-blinded, placebo-controlled design, 178 participants with nonobstructive HCM (age, 23.3±10.1 years; 61% men) were randomized in the primary cohort and 34 (age, 16.5±4.9 years; 50% men) in the exploratory cohort of sarcomeric mutation carriers without left ventricular hypertrophy.

resultsIn the primary cohort, maximal left ventricular wall thickness was 17±4 mm for adults and

conclusionsThe VANISH cohort is much larger, younger, less heterogeneous, and has less advanced disease than prior angiotensin receptor blocker trials in HCM. Participants had relatively normal functional capacity and mild HCM features. New York Heart Association functional class II symptoms were associated with older age, more prominent imaging abnormalities, and CLINICAL

trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01912534.

Indexed as

MutationAdolescentAdultAngiotensin II Type 1 Receptor BlockersBrazilCanadaCardiomyopathy, HypertrophicChildDenmarkDisease ProgressionDouble-Blind MethodFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedAngiotensin II Type 1 Receptor BlockersValsartanangiotension receptor blockercardiomyopathy, hypertrophicrandomized controlled trial

Identifiers

PMID31813281
PMCPMC7219518
OpenAlexW2992779961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.